Trial reportAddictive behaviors2012
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.
Trial report in Addictive behaviors, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 5 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.Epidemiologic reviews · 2020Pooled it
- Buprenorphine for managing opioid withdrawal.The Cochrane database of systematic reviews · 2017Pooled it
- Maintenance treatments for opiate -dependent adolescents.The Cochrane database of systematic reviews · 2014Pooled it
- Detoxification treatments for opiate dependent adolescents.The Cochrane database of systematic reviews · 2014Pooled it
- Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.The Cochrane database of systematic reviews · 2014Pooled it
- Trial
- Extended-release naltrexone for youth with opioid use disorder.Journal of substance abuse treatment · 2021Trial
- Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.The American journal on addictions · 2021Trial
- MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.Addiction science & clinical practice · 2018Trial
- Characterizing opioid withdrawal during double-blind buprenorphine detoxification.Drug and alcohol dependence · 2015Trial
- Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.The Journal of clinical psychiatry · 2015Trial
- Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.Drug and alcohol dependence · 2015Trial
- Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual.Journal of addiction medicineTrial
- Review
- Predicting treatment retention in medication for opioid use disorder: a machine learning approach using NLP and LLM-derived clinical features.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Exploring the Determinants of Treatment Completion Among Youth Who Received Medication-Assisted Treatment in the United States.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Evaluation of adherence monitoring in buprenorphine treatment: A pilot study using timed drug assays to determine accuracy of testing.British journal of clinical pharmacology · 2023Article
- Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Article
- Assessing the feasibility, usability and acceptability of theDrug and alcohol dependence reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundIn opioid dependent youth there is substantial attrition from medication-assisted treatment. If youth at risk for attrition can be identified at treatment entry or early in treatment, they can be targeted for interventions to help retain them in treatment.
methodsOpioid dependent adolescents and young adults (n=152), aged 15-21, were randomized to 12 weeks (BUP, n=74) or 2 weeks of detoxification (DETOX, n=78) with buprenorphine/naloxone (Bup/Nal), both in combination with 12 weeks of psychosocial treatment. Baseline and early treatment related predictors of treatment attrition were identified in each group using bivariate and multivariate logistic regression.
resultsIn the DETOX group 36% left between weeks 2 and 4, at the end of the dose taper, while in the BUP group only 8% left by week 4. In the BUP group, early adherence to Bup/Nal, early opioid negative urines, use of any medications in the month prior to treatment entry, and lifetime non-heroin opioid use were associated with retention while prior 30-day hallucinogen use was associated with attrition. In the DETOX group, only use of sleep medications was associated with retention although not an independent predictor. A broad range of other pre-treatment characteristics was unrelated to attrition.
conclusionsPrompt attention to those with early non-adherence to medication or an early opioid positive urine, markers available in the first 2 weeks of treatment, may improve treatment retention. Extended Bup/Nal treatment appeared effective in improving treatment retention for youth with opioid dependence across a wide range of demographics, and pre-treatment clinical characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.